EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Non-HLA Antibodies in Kidney Transplantation: Mediators of Allograft Injury or Markers of Dysregulated Humoral Immunity?

Ariadni Fouza, Maria Daoudaki iD

Medical Sciences · 2026

DOI: 10.3390/medsci14050534 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medical Sciences, 2026. Verfasst von Ariadni Fouza und 1 weiteren Autor:innen. Beteiligte Einrichtung: 5th Surgical Department, Hippokratio General Hospital, School of Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece. Hauptthemen laut MEDLINE: Kidney Transplantation, Immunity, Humoral, Graft Rejection, Allografts. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-mediated rejection (AMR) remains a major cause of kidney allograft injury and loss. Although donor-specific antibodies against human leukocyte antigens (HLA-DSAs) are central to humoral alloimmunity, they do not explain all cases of microvascular inflammation or graft dysfunction. This review critically evaluates non-HLA antibodies as potential mediators of allograft injury and markers of dysregulated humoral immunity by integrating functional, experimental, clinicopathological, and clinical evidence. Receptor-targeting antibodies, especially those against the angiotensin II type 1 receptor (AT1R) and the endothelin-1 type A receptor (ETAR), have the strongest evidence for direct pathogenicity. Antibodies against major histocompatibility complex class I-related chain A (MICA) and glutathione S-transferase theta-1 (GSTT1) reflect non-HLA alloimmunity, whereas antibodies targeting perlecan-derived LG3, vimentin, and injury-associated antigens may arise through secondary autoimmunity and mark broader humoral activation. We propose that selected pathogenic non-HLA antibodies participate in a feed-forward cycle of graft injury, antigen exposure, epitope spreading, and humoral amplification, although this model requires longitudinal validation. Crucially, non-HLA antibody positivity alone should neither establish AMR nor guide antibody-specific treatment. Its interpretation should be target-specific and integrated with HLA-DSAs, histopathology, molecular findings, graft function, and evidence of immune activation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationImmunity, HumoralGraft RejectionAllograftsAntibodiesHumansHLA AntigensBiomarkersAnimals

Stichwörter der Autor:innen

antibody-mediated rejectionendothelial injuryhumoral immunitykidney transplantationnon-HLA antibodiesprecision immune monitoring

Substanzen

HLA AntigensBiomarkersAntibodies

Autor:innen und Institutionen

  • 5th Surgical Department, Hippokratio General Hospital, School of Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.
  • Department of Transplant Surgery, Center for Research and Innovation in Solid Organ Transplantation, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
  • Laboratory of Biological Chemistry, School of Medicine, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece.

ORCID-Profile: Maria Daoudaki

Zitieren

APA

Fouza, A., & Daoudaki, M. (2026). Non-HLA Antibodies in Kidney Transplantation: Mediators of Allograft Injury or Markers of Dysregulated Humoral Immunity?. Medical Sciences. https://doi.org/10.3390/medsci14050534

Vancouver

Fouza A, Daoudaki M. Non-HLA Antibodies in Kidney Transplantation: Mediators of Allograft Injury or Markers of Dysregulated Humoral Immunity?. Medical Sciences. 2026. doi:10.3390/medsci14050534

BibTeX
@article{Fouza2026,
  author = {Fouza, Ariadni and Daoudaki, Maria},
  title = {Non-HLA Antibodies in Kidney Transplantation: Mediators of Allograft Injury or Markers of Dysregulated Humoral Immunity?},
  journal = {Medical Sciences},
  year = {2026},
  doi = {10.3390/medsci14050534}
}
Kostenlos starten →